To The Moon

Shares of Hims & Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and erectile dysfunction, directly competing with the telehealth startup.Amazon on Thursday launched the treatments through its One Medical telehealth service, and Amazon Prime members are eligible for free shipping, the company said.Hims & Hers's stock is down 25% in Thursday trading. Shares have more than doubled this year, due in part to the company's introduction of weight-loss treatments in May. Amazon's online pharmacy partnered with Lilly in March to fill prescriptions for the weight-loss drug Zepbound.Hims & Hers gained popularity as one of the first companies to directly ship hair and skin treatments to telehealth patients. The company said this month it had more than 2 million subscribers in the third quarter, a 40% boost from a year ago.Amazon's push into low-cost treatments follows its launch of Haul, a budget online storefront similar to Temu or Shein.Ama

远程医疗公司Hims & Hers Health Inc.(HIMS.us)于2024年10月30日盘中股价大跌16.06%,引发市场关注。 根据分析师看法,这很可能与该公司减肥药业务所面临的竞争加剧有关。 10月30日,诺和诺德公司的减肥药Wegovy在美国获准上市所有五种剂量强度。这一竞品进入市场或引发了投资者对Hims & Hers Health在减肥药领域业务前景的担忧。 分析机构Leerink Partners指出,尽管GLP-1类似减肥药营收目前在公司总收入中仍占比很小,但HIMS的股价波动可能会受到相关新闻的影响。这种风险可能导致股价经历不必要的大起大落。

Hims & Hers (NYSE:HIMS), the telehealth platform that offers compounded versions of weight loss drugs, dropped more than 10% on Thursday after the FDA confirmed that Eli Lilly's (LLY) GLP-1 tirzepatid

Shares of Hims & Hers Health Inc. plunged nearly 8% in pre-market trading on Wednesday, as investors reacted to concerns over the potential end of a shortage that has allowed the telehealth company to offer affordable versions of popular weight-loss drugs.Hims & Hers has been selling compounded versions of drugs like Wegovy and Ozempic, which are used for weight loss and diabetes treatment, at a fraction of the cost charged by pharmaceutical giants Eli Lilly and Novo Nordisk. The company has be